National Centre for Pharmacoeconomics

National Centre for

NCPE Ireland

Pembrolizumab (Keytruda®) for NSCLC (second line)

Pembrolizumab (Keytruda®) is indicated for the treatment of locally advanced or metastatic non-small cell lung carcinoma (NSCLC) in adults whose tumours express PD-L1 and who have received at least one prior chemotherapy regimen. Patients with EGFR or ALK positive tumour mutations should also have received approved therapy for these mutations prior to receiving pembrolizumab.

NCPE Assessment Process Complete
Rapid review received 03/08/2016
Rapid review completed 24/08/2016
Rapid Review outcome Full pharmacoeconomic assessment recommended
Full pharmacoeconomic assessment commissioned by HSE 31/08/2016
Pre-submission consultation with Applicant 10/10/2016
Submission received from Applicant 21/07/2017
Preliminary review sent to Applicant 23/10/2017
Preliminary response received from Applicant 05/03/2018
NCPE assessment re-commenced 06/03/2018
Factual accuracy sent to applicant 17/05/2018
NCPE assessment re-commenced 25/05/2018
NCPE assessment completed 28/05/2018
NCPE assessment outcome The NCPE recommends that pembrolizumab (Keytruda) be considered for reimbursement if cost-effectiveness can be improved relative to existing treatments. This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.


Reimbursement application withdrawn (November 2018)